The present invention relates to using monoterpene or sesquiterpene to permeabilize the blood brain barrier.

Described herein are compositions and methods for treating Alzheimer's disease or dementia. The compositions include mammalian suppressor of taupathy 2 inhibitors (MSUT2). The MSUT2 inhibitors can be small interfering RNAs, guide RNAs, or small molecules. The methods include reducing accumulation of phosphorylated and aggregated human tau.

A method for treating influenza is described. The disclosed method generally involves administering an effective amount of a compound, for example baloxavir marboxil, to a subject having influenza, where the compound is administered initially at least about 48 hours after an onset of influenza. Generally, the effective amount is sufficient to alleviate a symptom of influenza in the subject as compared to a symptom that the subject has when the compound is first administered to the subject.

Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, a syndrome due to androgen excess, and/or a syndrome due to glucocorticoid excess such as hypercortisolemia.

The present invention provides methods to prevent the formation of visible particles in aqueous protein formulations, in particular the use of certain chelators, as well as compositions and pharmaceutical products obtained with said method.

A suxamethonium pharmaceutical composition including suxamethonium chloride and a succinic acid buffer. Also, a prefilled syringe thereof and a process of sterilizing the suxamethonium prefilled syringe. The composition and the prefilled syringe are useful as ready-to-use formulations, especially in emergency conditions, and present long shelf lives, even at room temperature.

The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

An intravenous composition for providing relief for pain and/or inflammation, the composition having ibuprofen and paracetamol in combination for delivering to a human at each dose: a) approximately 125 mg to approximately 175 mg ibuprofen in combination with approximately 475 mg to approximately 525 mg paracetamol; or b) approximately 275 mg to approximately 325 mg ibuprofen in combination with approximately 975 mg to approximately 1,025 mg paracetamol.

A composition comprising mesoporous silica rods comprising an immune cell recruitment compound and an immune cell activation compound, and optionally comprising an antigen such as a tumor lysate. The composition is used to elicit an immune response to a vaccine antigen.

The present invention relates to a compound according to formula (I) Formula (I) a physiologically acceptable salt, a solvate, or a hydrate thereof for use in the prevention and/or treatment of diseases caused by betacorona-virus infection in a mammalian subject, such as a human, wherein said compound is administered by inhalation as a pharmaceutical composition comprising preferably alcohol as a carrier. A preferred example is viral infection caused by SARS.

##STR00001##